Renal disease: a common and a silent killer

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Traditional cardiovascular risk factors do not fully explain remaining cardiovascular mortality and morbidity.
• New risk factors and therapeutic targets are needed for comprehensive cardiovascular disease (CVD) management.
• Renal dysfunction is increasingly recognized as a significant contributor to CVD risk.

Purpose of the Study:

• To present evidence linking renal dysfunction to cardiovascular risk.
• To highlight the prevalence of renal dysfunction in the general and CVD populations.
• To discuss therapeutic strategies targeting renal function for cardiovascular benefit.

Main Methods:

• Review of epidemiological data on renal dysfunction prevalence (low glomerular filtration rate, albuminuria, anemia).
• Analysis of the independent and additive nature of renal dysfunction as a cardiovascular risk factor.
• Discussion of treatment strategies, including renin-angiotensin-aldosterone system interventions.

Main Results:

• 10-11% of the general population have low glomerular filtration rates; 5-7% have increased urinary albumin excretion; 5-10% have anemia.
• Each feature of renal dysfunction independently and additively increases cardiovascular risk.
• Treatments for renal dysfunction can reduce both cardiovascular and renal risk.

Conclusions:

• Renal dysfunction is a common and potent cardiovascular risk factor.
• Improving renal function through targeted therapies offers significant cardiovascular benefits.
• Interventions targeting albuminuria, such as renin-angiotensin-aldosterone system blockade, reduce cardiovascular and renal risk, particularly in conditions like type 2 diabetes.